STXS Share Price | Stereotaxis, Inc. Stock Analysis & Recommendation

Q: What does Stereotaxis, Inc. do?

Overview: Stereotaxis, Inc. is a United States-based healthcare technology company engaged in the development of robotic cardiology instrument navigation systems, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.Financial Snapshot: Most recent Net Sales: 7 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025) Market cap: USD 195.23 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.24 Return on Equity: -310.19% Price to Book: 23.88Contact Details: Address: 4320 Forest Park Ave Ste 100, ST. LOUIS MO: 63108-2979 Tel: 1 314 6786100 Fax: 1 314 6786159 Website: http://www.stereotaxis.com

Q: Is Stereotaxis, Inc. overvalued or undervalued?

As of 9 May 2019, the valuation grade for Stereotaxis, Inc. moved from fair to risky, indicating a deterioration in its investment appeal. The company is overvalued, as evidenced by its high Price to Book Value of 23.67 and negative EV to EBIT and EV to EBITDA ratios of -7.08 and -7.42, respectively. Additionally, the Return on Equity (ROE) is alarmingly low at -310.19%, reflecting significant financial distress.In comparison to its peers, Stereotaxis, Inc. exhibits a notably worse valuation profile; for instance, Bioventus, Inc. has a P/E ratio of 72.81, while Semler Scientific, Inc. is considered attractive with a P/E ratio of 32.26. The stock has shown mixed performance against the S&P 500, with a year-to-date return of 22.81% compared to the index's 12.22%, but a disappointing 5-year return of -25.73% versus the S&P 500's impressive 96.61%.

Q: Is Stereotaxis, Inc. technically bullish or bearish?

As of 8 August 2025, the technical trend for Stereotaxis, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, supporting the positive trend. However, the weekly RSI is bearish, indicating some short-term weakness. The daily moving averages are bullish, and the KST is bullish on both weekly and monthly time frames. The Bollinger Bands show a mildly bullish stance on both weekly and monthly periods. The Dow Theory indicates a mildly bullish trend on the weekly chart but no trend on the monthly.In terms of performance, Stereotaxis has outperformed the S&P 500 year-to-date with a return of 22.81% compared to the S&P's 12.22%, and over the past year, it has returned 43.59% versus the S&P's 17.14%. However, over longer periods, such as 3 years and 5 years, it has significantly underperformed the benchmark.Overall, the current technical stance is bullish, driven primarily by the MACD and moving averages, despite some mixed signals from the RSI and Dow Theory.

Results Declared: Stereotaxis, Inc. has declared results on 09 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

53.4 k

Shareholding (Dec 2025)

FII

1.54%

Held by 27 FIIs

DII

89.73%

Held by 13 DIIs

Promoter

0.00%

How big is Stereotaxis, Inc.?

22-Jun-2025

As of Jun 18, Stereotaxis, Inc. has a market capitalization of 195.23 million and reported net sales of 27.51 million, with a net loss of 25.35 million over the latest four quarters. Shareholder's funds are at 11.43 million, and total assets amount to 46.72 million.

View full answer

What does Stereotaxis, Inc. do?

22-Jun-2025

Stereotaxis, Inc. is a U.S. healthcare technology company specializing in robotic cardiology instrument navigation systems, with a market cap of $195.23 million and recent net sales of $7 million. The company reported a net loss of $6 million for the quarter ending March 2025.

View full answer

Who are in the management team of Stereotaxis, Inc.?

22-Jun-2025

As of March 2022, the management team of Stereotaxis, Inc. includes Chairman and CEO David Fischel, Lead Independent Director David Benfer, Directors Nathan Fischel, Joseph Kiani, Ross Levin, and Independent Director Arun Menawat. They oversee the company's strategic direction and governance.

View full answer

Is Stereotaxis, Inc. overvalued or undervalued?

20-Sep-2025

As of May 9, 2019, Stereotaxis, Inc. is considered a risky investment due to its high Price to Book Value of 23.67, negative EV to EBIT and EV to EBITDA ratios, and a low Return on Equity of -310.19%, especially when compared to peers like Bioventus and Semler Scientific, despite a year-to-date return of 22.81% against the S&P 500's 12.22%.

View full answer

Is Stereotaxis, Inc. technically bullish or bearish?

20-Sep-2025

As of August 8, 2025, Stereotaxis, Inc. shows a bullish technical trend supported by positive MACD and moving averages, despite a bearish weekly RSI and mixed signals from Dow Theory, while outperforming the S&P 500 year-to-date and over the past year, but underperforming over longer periods.

View full answer

Compare Stereotaxis, Inc. with Similar Stocks

Xtant Medical Holdings, Inc.Sight Sciences, Inc.Semler Scientific, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 186 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.86

Return on Equity

-193.13%

Price to Book

16.10

Revenue and Profits:

Net Sales:

9 Million

(Quarterly Results - Dec 2025)

Net Profit:

-6 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-20.69%

6 Months

-34.29%

1 Year

-0.54%

2 Years

-25.81%

3 Years

-5.15%

4 Years

-53.54%

5 Years

-73.37%

Stereotaxis, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

2.41%

EBIT Growth (5y)

-206.71%

EBIT to Interest (avg)

-17.77

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.24

Sales to Capital Employed (avg)

1.98

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

50.35%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

16.10

EV to EBIT

-7.73

EV to EBITDA

-8.29

EV to Capital Employed

106.52

EV to Sales

5.85

PEG Ratio

Dividend Yield

ROCE (Latest)

-1377.29%

ROE (Latest)

-193.13%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 17 Schemes (8.73%)

Foreign Institutions

Held by 27 Foreign Institutions (1.54%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 14.67% vs -14.77% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 15.38% vs -71.05% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8.60",
          "val2": "7.50",
          "chgp": "14.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.90",
          "val2": "-4.80",
          "chgp": "-2.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.40",
          "val2": "-1.40",
          "chgp": "71.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.50",
          "val2": "-6.50",
          "chgp": "15.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-608.50%",
          "val2": "-697.50%",
          "chgp": "8.90%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 20.45% vs 0.37% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 10.00% vs -15.94% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "32.40",
          "val2": "26.90",
          "chgp": "20.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-18.40",
          "val2": "-23.80",
          "chgp": "22.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-21.60",
          "val2": "-24.00",
          "chgp": "10.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-615.00%",
          "val2": "-919.10%",
          "chgp": "30.41%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

8.60

7.50

14.67%

Operating Profit (PBDIT) excl Other Income

-4.90

-4.80

-2.08%

Interest

0.00

Exceptional Items

-0.40

-1.40

71.43%

Consolidate Net Profit

-5.50

-6.50

15.38%

Operating Profit Margin (Excl OI)

-608.50%

-697.50%

8.90%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 14.67% vs -14.77% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 15.38% vs -71.05% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

32.40

26.90

20.45%

Operating Profit (PBDIT) excl Other Income

-18.40

-23.80

22.69%

Interest

0.00

Exceptional Items

-2.20

0.00

Consolidate Net Profit

-21.60

-24.00

10.00%

Operating Profit Margin (Excl OI)

-615.00%

-919.10%

30.41%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 20.45% vs 0.37% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 10.00% vs -15.94% in Dec 2024

All Annual Results

Company CV

About Stereotaxis, Inc.

Stereotaxis, Inc.

Pharmaceuticals & Biotechnology

Stereotaxis, Inc. is a United States-based healthcare technology company. The Company is engaged in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease. The Company also provides information management solutions for the interventional lab. The Stereotaxis platform helps physicians to provide patient care with robotic precision and enhanced integration of procedural information. The Company’s Epoch solution includes the Niobe ES remote magnetic navigation system, the Odyssey portfolio of lab optimization, networking and patient information management systems, and the Vdrive robotic navigation system and consumables. The Niobe ES remote magnetic navigation system includes the Navigant software user interface and the QuikCAS catheter advancement system. The Vdrive robotic navigation system with Niobe ES magnetic navigation system provides navigation and stability for diagnostic and ablation devices.

Company Coordinates

Company Details

4320 Forest Park Ave Ste 100 , ST. LOUIS MO : 63108-2979

Tel: 1 314 6786100

http://www.stereotaxis.com

Registrar Details